Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma.
Nasal and nasal-type natural killer (NK) lymphoma is a distinct clinicopathological entity mostly associated with Epstein-Barr virus. Cases that have widespread lesions are resistant to ordinary anti-cancer therapy and take a highly aggressive course. To date, there are no available data on the relationships between the localization, clinical outcome and expression of adhesion molecules in such cases. We examined the expression of cutaneous lymphocyte antigen (CLA) in 52 cases of NK-cell lymphoma. CLA was highly expressed in cutaneous cases. Also, the CLA+ group (n=29) had a much worse prognosis than the CLA- group (n=23), regardless of the primary site or clinical staging. Univariate analysis identified some significant prognostic factors, and multivariate analysis of these factors showed that the expression of CLA was an independent prognostic indicator. In conclusion, the present findings established that CLA is an independent and important prognostic factor in patients with NK-cell lymphomas.
Yoshino
Tadashi
T
Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan. yoshino@md.okayama-u.ac.jp
Nakamura
Shigeo
S
Suzumiya
Junji
J
Niitsu
Nozomi
N
Ohshima
Koichi
K
Tsuchiyama
Junjiro
J
Shinagawa
Katsuji
K
Tanimoto
Mitsune
M
Sadahira
Yoshito
Y
Harada
Mine
M
Kikuchi
Masahiro
M
Akagi
Tadaatsu
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D015999:Multivariate Analysis; D009669:Nose Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy; D016019:Survival Analysis
D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; C063419:CTAGE1 protein, human; D008562:Membrane Glycoproteins